- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03953196
A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants
January 27, 2020 updated by: Janssen Research & Development, LLC
A Phase 0 Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Volunteers
The purpose of this study is to characterize the immune response in vivo using approved vaccines and antigen challenges, as well as a skin wounding challenge to stimulate the immune system.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Merksem, Belgium, 2170
- Clinical Pharmacology Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have a body mass index (BMI) between 18 and 30 kilogram per square meter (kg/m^2) (BMI = weight/height^2), inclusive, and a body weight of no less than 50 kilogram (kg)
- Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) (for Cohort 3) performed at screening. Any abnormalities, must be considered not clinically significant and this determination must be recorded in the participant's source documents and initialed by the investigator
- Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, blood coagulation, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
- Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
- All women must have a negative highly sensitive serum (Beta-human chorionic gonadotropin [Beta-hCG]) pregnancy test at screening and a negative urine pregnancy test predose on Day 1
Exclusion Criteria:
- History of any type of immunodeficiency or autoimmune disease or disease treatment associated with immune suppression or lymphopenia. These include but are not limited to bone marrow or organ transplantation, lymphoproliferative disorders, T- or B-cell deficiency syndromes, splenectomy, functional asplenia and chronic granulomatous disease
- History of liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, bleeding disorders, rheumatologic, psychiatric, or metabolic disturbances, and atopic dermatitis
- Known allergies, hypersensitivity, or intolerance to any of the interventions in this study or their excipients
- History of severe allergic reaction, angioedema, or anaphylaxis to drugs or food
- Contraindications to the use of any of the study interventions per prescribing information
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: Vaccine Challenge Imvanex
Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.
|
Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
Other Names:
|
Experimental: Cohort 2: Vaccine Challenge Shingrix
Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.
|
Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
|
Experimental: Cohort 3: Antigen Challenge Lipopolysaccharides (LPS)
Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.
|
LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
Other Names:
|
Experimental: Cohort 4: Antigen Challenge Candin
Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.
|
Candin 0.1 mL solution for injection will be administered as one intradermal injection.
Other Names:
Saline control solution for injection will be administered as one intradermal injection.
|
Experimental: Cohort 5: Skin Wounding Challenge
3 punch biopsies will be performed per standard dermatologic practice guidelines.
Lower abdomen tissue biopsy specimens will be collected on Day 1.
|
3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort 1 and Cohort 2: Change from Baseline of Immune Cell Populations
Time Frame: Baseline up to 90 days
|
Change from baseline in immune cell populations will be measured in peripheral blood samples or tissues of healthy volunteers.
|
Baseline up to 90 days
|
Cohort 3 and Cohort 4: Change from Baseline of Immune Cell Populations
Time Frame: Baseline up to 14 days
|
Change from baseline in immune cell populations will be measured in peripheral blood samples or tissues of healthy volunteers.
|
Baseline up to 14 days
|
Cohort 5: Change from Baseline of Immune Cell Populations
Time Frame: Baseline up to 10 days
|
Change from baseline in immune cell populations will be measured in tissues of healthy volunteers.
|
Baseline up to 10 days
|
Cohort 1 and Cohort 2: Change from Baseline in Cell Surface Antigen Phenotype
Time Frame: Baseline up to 90 days
|
Change from baseline in cell surface antigen phenotype will be measured in peripheral blood samples or tissues of healthy volunteers.
|
Baseline up to 90 days
|
Cohort 3 and Cohort 4: Change from Baseline in Cell Surface Antigen Phenotype
Time Frame: Baseline up to 14 days
|
Change from baseline in cell surface antigen phenotype will be measured in peripheral blood samples or tissues of healthy volunteers.
|
Baseline up to 14 days
|
Cohort 5: Change from Baseline in Cell Surface Antigen Phenotype
Time Frame: Baseline up to 10 days
|
Change from baseline in cell surface antigen phenotype will be measured in tissues of healthy volunteers.
|
Baseline up to 10 days
|
Cohort 1 and Cohort 2: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)
Time Frame: Baseline up to 90 days
|
Soluble cytokines and chemokines will be measured by immunoassay.
|
Baseline up to 90 days
|
Cohort 3 and Cohort 4: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)
Time Frame: Baseline up to 14 days
|
Soluble cytokines and chemokines will be measured by immunoassay.
|
Baseline up to 14 days
|
Cohort 5: Change from Baseline in Activation Status of Inflammatory Mediators (Soluble Cytokines and Chemokines)
Time Frame: Baseline up to 10 days
|
Soluble cytokines and chemokines will be measured by immunoassay.
|
Baseline up to 10 days
|
Cohort 1 and Cohort 2: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)
Time Frame: Baseline up to 90 days
|
Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.
|
Baseline up to 90 days
|
Cohort 3 and Cohort 4: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)
Time Frame: Baseline up to 14 days
|
Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.
|
Baseline up to 14 days
|
Cohort 5: Change from Baseline in Activation Status of Inflammatory Mediators (Cell-bound and Tissue-associated Proteins)
Time Frame: Baseline up to 10 days
|
Cell-bound and tissue-associated proteins will be measured by established methods including flow cytometry and immunohistochemistry.
|
Baseline up to 10 days
|
Cohort 1 and Cohort 2: Change from Baseline in Expression of Inflammatory Mediators
Time Frame: Baseline up to 90 days
|
Transcriptional changes in gene expression will be measured by established methods such as ribonucleic acid (RNA) microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.
|
Baseline up to 90 days
|
Cohort 3 and Cohort 4: Change from Baseline in Expression of Inflammatory Mediators
Time Frame: Baseline up to 14 days
|
Transcriptional changes in gene expression will be measured by established methods such as ribonucleic acid (RNA) microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.
|
Baseline up to 14 days
|
Cohort 5: Change from Baseline in Expression of Inflammatory Mediators
Time Frame: Baseline up to 10 days
|
Transcriptional changes in gene expression will be measured by established methods such as RNA microarray, RNAseq, and single cell RNA sequencing, and will be reported in number of gene transcripts per sample or per cell.
|
Baseline up to 10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Standard Deviation from Baseline of Immune Cell Populations Within a Participant
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in standard deviation from baseline of immune cell populations within a participant will be measured.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in Standard Deviation from Baseline of Immune Cell Populations Between Participants
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in standard deviation from baseline of immune cell populations between participants will be measured.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in Standard Deviation from Baseline in Cell Surface Antigen Phenotype Within a Participant
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in standard deviation from baseline in cell surface antigen phenotype within a participant will be measured.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in Standard Deviation from Baseline in Cell Surface Antigen Phenotype Between Participants
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in standard deviation from baseline in cell surface antigen phenotype between participants will be measured.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in Standard Deviation from Baseline in Activation Status of Inflammatory Mediators Within a Participant
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in standard deviation from baseline in activation status of inflammatory mediators within a participant will be measured.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in Standard Deviation from Baseline in Activation Status of Inflammatory Mediators Between Participants
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in standard deviation from baseline in activation status of inflammatory mediators between participants will be measured.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in Standard Deviation from Baseline in Expression of Inflammatory Mediators Within a Participant
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in standard deviation from baseline in expression of inflammatory mediators within a participant will be measured.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in Standard Deviation from Baseline in Expression of Inflammatory Mediators Between Participants
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Change in standard deviation from baseline in expression of inflammatory mediators between participants will be measured.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days; Cohort 5: Baseline up to 10 days
|
Correlation of Baseline Immune Cell Populations with Vaccine/Antigen Immune Response Phenotype
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
|
Correlation of baseline immune cell populations with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
|
Correlation of Genomics with Vaccine/Antigen Immune Response Phenotype
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
|
Correlation of genomics with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
|
Correlation of Serology with Vaccine/Antigen Immune Response Phenotype
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
|
Correlation of serology with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
|
Correlation of Soluble Proteins with Vaccine/Antigen Immune Response Phenotype
Time Frame: Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
|
Correlation of soluble proteins with vaccine/antigen immune response phenotype will be measured by phenotypic and functional assays.
|
Cohort 1 and Cohort 2: Baseline up to 90 days; Cohort 3 and Cohort 4: Baseline up to 14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 8, 2019
Primary Completion (Actual)
December 26, 2019
Study Completion (Actual)
December 26, 2019
Study Registration Dates
First Submitted
April 1, 2019
First Submitted That Met QC Criteria
May 15, 2019
First Posted (Actual)
May 16, 2019
Study Record Updates
Last Update Posted (Actual)
January 29, 2020
Last Update Submitted That Met QC Criteria
January 27, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- CR108590
- NOPRODNAP0016 (Other Identifier: Janssen Research & Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Imvanex
-
Bavarian NordicNational Institutes of Health (NIH)CompletedHIV InfectionsUnited States, Puerto Rico
-
Bavarian NordicUS Army Medical Research Institute of Infectious DiseasesCompleted18-42 Year Old Healthy Vaccinia-naïve SubjectsKorea, Republic of
-
Bavarian NordicCompleted
-
Bavarian NordicCompleted
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingMonkey Pox | Monkey DiseasesFrance
-
Centers for Disease Control and PreventionBavarian Nordic; Kinshasa School of Public Health; Ministry of Public Health,...Active, not recruitingMonkeypox Virus InfectionCongo, The Democratic Republic of the